Dr. Messmann has extensive clinical and commercial experience as a medical oncologist and drug-development physician. He had fellowship training at the National Cancer Institute (NCI) prior to becoming deputy associate director of the NCI Developmental Therapeutics Program. He has also served as VP of Medical Affairs for Endocyte, Director of Cancer Research for the Great Lakes Cancer Institute at Michigan State University.

Ms. Sooch brings with her over twenty years of pharmaceutical and healthcare experiences as an entrepreneur and operator, strategy & finance advisor, and venture capitalist. Prior to venture capital, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity com

Dr. Rodrigueza, whose therapeutic research expertise includes cardiovascular disease, oncology, diabetes and metabolic diseases, joins ProNAi after most recently serving at Novartis Institute of Biomedical Research, Inc. (NIBRI) as Director, Product Management, Cardiovascular Disease Area. Prior to NIBRI, Dr. Rodrigueza held numerous senior research positions at both CuraGen and Esperion Therapeutics.